Search results
InnoCare Pharma concludes subject enrolment Phase II psoriasis trial
Clinical Trials Arena via Yahoo Finance· 10 hours agoInnoCare Pharma has announced the completion of subject enrolment in the Phase II clinical trial of...
Bryhali dosage: Form, strength, how to use, and more
Medical News Today· 6 days agoBryhali (halobetasol) is a brand-name drug prescribed to treat plaque psoriasis in adults. Bryhali belongs to a drug class called corticosteroids. Note:...
Analyst Report: Biogen Inc
Argus Research via Yahoo Finance· 1 day agoThe company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also ...
Q1 2024 Arcutis Biotherapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 1 day agoThe value propositions retreat resonate with prescribers and aim to resolve plaque that can affect many different parts of the body, hard-to-treat areas like elbows and knees ...
Stelara interactions: Other medications, alcohol, and more
Medical News Today· 6 days agoStelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions....
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition...
Rome Sentinel· 7 days agoAdalimumab-aaty is also available from Celltrion USA under the brand name YUFLYMA®, which launched in July 2023 and is available at a 5% discount to the current WAC list price of HUMIRA. Adalimumab-aaty ...
Earnings call: Arcutis Biotherapeutics reports strong Q1 2024 growth
Investing.com· 2 days agoArcutis expressed confidence in its growth trajectory, citing improvements in gross-to-net (GTN)...
It Took Me Years to Find the Right Psoriatic Arthritis Medication
Verywell Health via Yahoo News· 2 days agoAfter being diagnosed with psoriatic arthritis in 2016, it took LB Herbert years to find a psoriatic...
AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research Forecasts
ETF DAILY NEWS· 16 hours agoAbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Zacks Research lifted their Q2 2024 earnings estimates for shares of AbbVie in a research report issued to clients and investors on Tuesday ...
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides...
WKRN Nashville· 23 hours agoScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing ...
